Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

28.6%

6 terminated/withdrawn out of 21 trials

Success Rate

53.8%

-32.7% vs industry average

Late-Stage Pipeline

10%

2 trials in Phase 3/4

Results Transparency

100%

7 of 7 completed trials have results

Key Signals

3 recruiting7 with results

Enrollment Performance

Analytics

Phase 2

9(42.9%)

Phase 1

9(42.9%)

Phase 3

2(9.5%)

Early Phase 1

1(4.8%)

21Total

Phase 2(9)

Phase 1(9)

Phase 3(2)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (21)

Showing 20 of 21 trials

NCT03701334Phase 3Active Not Recruiting

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

Role: collaborator

NCT04777851Phase 3Terminated

Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7

Role: lead

NCT05103683Phase 1Recruiting

First in Human Study of TORL-1-23 in Participants With Advanced Cancer

Role: collaborator

NCT05156866Phase 1Active Not Recruiting

First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer

Role: collaborator

NCT03672773Phase 2Active Not Recruiting

Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

Role: collaborator

NCT05948826Phase 1Active Not Recruiting

First in Human Study of TORL-3-600 in Participants With Advanced Cancer

Role: collaborator

NCT06005740Phase 1Recruiting

A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

Role: collaborator

NCT05159440Phase 1Active Not Recruiting

First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer

Role: collaborator

NCT05103046Phase 1Recruiting

First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors

Role: collaborator

NCT05582031Phase 2Withdrawn

Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers

Role: lead

NCT02049593Phase 1Completed

PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Role: collaborator

NCT04261218Phase 1Completed

Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer

Role: lead

NCT02900560Phase 2Terminated

Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer

Role: lead

NCT02015559Phase 2Completed

Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus

Role: collaborator

NCT01784640Phase 1Completed

Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer

Role: collaborator

NCT03004534Early Phase 1Completed

A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide

Role: lead

NCT02115048Phase 2Terminated

Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone

Role: lead

NCT00777049Phase 2Completed

Study of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer

Role: lead

NCT00718523Phase 2Terminated

Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer

Role: lead

NCT00719212Phase 2Completed

Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer

Role: lead